Other languages Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Market Closed - Swiss Exchange Other stock markets 11:31:51 2024-04-24 am EDT			5-day change	1st Jan Change
9.46 ^CHF	-1.97%		-3.96%	-3.57%

08:22am	Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	MT
07:00am	Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	02:22am
Santhera dans les chiffres noirs en 2023	02:02am
Santhera dank Catalyst-Deal mit gutem Finanzpuffer - ab 2026 Break-Even geplant	02:01am
Spexis: sursis concordataire prolongé de 4 mois après réception d'un paiement	Apr. 17
Santhera obtient un statut d'examen prioritaire en Chine pour le vamorolone	Mar. 27
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	Mar. 27
Santhera kommt mit möglicher Zulassung von Vamorolon in China entscheidend voran	Mar. 27
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	Mar. 14
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	Mar. 14
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21
Aktien Schweiz auf Erholungskurs	Feb. 14
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	Feb. 14
Santhera veröffentlicht Daten über Vamorolon in Fachjournal 'Neurology'	Feb. 14
Santhera lanciert DMD-Mittel Agamree zuerst in Deutschland - weltweite Premiere	Jan. 15
Santhera lance Agamree contre la myopathie en commençant par l'Allemagne	Jan. 15
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	Jan. 12
Santhera: feu vert pour le vamorolone contre la myopathie outre-Manche	Jan. 12
Santhera erhält nun auch in Grossbritannien Zulassung für Agamree	Jan. 12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Other languages

Filters